Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Single-nucleus RNA-Seq reveals singular gene signatures of human ductal cells during adaptation to insulin resistance
Ercument Dirice, Giorgio Basile, Sevim Kahraman, Danielle Diegisser, Jiang Hu, Rohit N. Kulkarni
Ercument Dirice, Giorgio Basile, Sevim Kahraman, Danielle Diegisser, Jiang Hu, Rohit N. Kulkarni
View: Text | PDF
Research Article Development Endocrinology

Single-nucleus RNA-Seq reveals singular gene signatures of human ductal cells during adaptation to insulin resistance

  • Text
  • PDF
Abstract

Adaptation to increased insulin demand is mediated by β cell proliferation and neogenesis, among other mechanisms. Although it is known that pancreatic β cells can arise from ductal progenitors, these observations have been limited mostly to the neonatal period. We have recently reported that the duct is a source of insulin-secreting cells in adult insulin-resistant states. To further explore the signaling pathways underlying the dynamic β cell reserve during insulin resistance, we undertook human islet and duct transplantations under the kidney capsule of immunodeficient NOD/SCID-γ (NSG) mouse models that were pregnant, were insulin-resistant, or had insulin resistance superimposed upon pregnancy (insulin resistance + pregnancy), followed by single-nucleus RNA-Seq (snRNA-Seq) on snap-frozen graft samples. We observed an upregulation of proliferation markers (e.g., NEAT1) and expression of islet endocrine cell markers (e.g., GCG and PPY), as well as mature β cell markers (e.g., INS), in transplanted human duct grafts in response to high insulin demand. We also noted downregulation of ductal cell identity genes (e.g., KRT19 and ONECUT2) coupled with upregulation of β cell development and insulin signaling pathways. These results indicate that subsets of ductal cells are able to gain β cell identity and reflect a form of compensation during the adaptation to insulin resistance in both physiological and pathological states.

Authors

Ercument Dirice, Giorgio Basile, Sevim Kahraman, Danielle Diegisser, Jiang Hu, Rohit N. Kulkarni

×

Figure 6

The “selenocysteine synthesis” and the “SRP-dependent co-translational protein targeting to the membrane” pathways modulate endocrine cell gene expression in ductal cells treated with insulin.

Options: View larger image (or click on image) Download as PowerPoint
The “selenocysteine synthesis” and the “SRP-dependent co-translational p...
(A) Scheme of the insulin treatment optimization experiment. (B–E) Expression levels of PCNA (B), NGN-3 (C), PDX1 (D), and NKX2.2 (E) in PANC-1 cells treated every 24 hours with either PBS (black bars) or human insulin at 2 (pink), 10 (red) or 20 μg/mL (dark red) for 3, 7, or 14 days. Data are represented as mean of fold change compared with PBS-treated cells ± SEM (n = 3). P < 0.05 was considered as significant using 2-way ANOVA following Dunnet’s multiple-comparison adjustment. (F) Scheme of the selenocysteine synthesis and SRP pathway inhibition experiment. (G) SCLY expression levels in scramble (green bars) and siSCLY PANC-1 cells (orange bars) at different time points. Data are represented as mean of fold change compared with scramble cells ± SEM (n = 3). P < 0.05 was considered as significant using 2-way ANOVA following Bonferroni’s multiple comparison adjustment. (H) SRPRA expression levels in scramble cells treated every 24 hours with DMSO + PBS (sc-DMSO-PBS, black) and siSCLY cells treated with ESI + PBS (siSCLY-ESI-PBS, blue). Data are represented as mean of fold change compared with PBS-treated cells ± SEM (n = 3). P < 0.05 was considered as significant using unpaired 2-tailed t test. (I–K) Expression levels of SEC61A2 (I), PDX1 (J), and PAX6 (K) in sc-DMSO-PBS cells (black), sc-DMSO cells treated with insulin (sc-DMSO-INS, red), siSCLY-ESI-PBS cells (blue), or siSCLY-ESI cells treated with insulin (siSCLY-ESI-INS, purple). Data are represented as mean of fold change compared with their respective PBS-treated cells ± SEM (n = 3). P < 0.05 was considered as significant using 1-way ANOVA following Bonferroni’s multiple-comparison test. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts